Peak

Peak Bio is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for oncology and inflammatory diseases. The company's lead candidate, PHP-303, is a potent, selective, oral small molecule neutrophil elastase inhibitor currently in Phase 2 development for Alpha-1 Antitrypsin Deficiency (AATD) and Acute Respiratory Distress Syndrome (ARDS). Peak Bio also utilizes a proprietary Antibody-Drug Conjugate (ADC) platform to create next-generation therapies for various solid tumors, targeting antigens such as TROP2. Despite its clinical progress, the company faced significant financial challenges and filed for Chapter 11 bankruptcy protection in early 2024. Peak Bio was previously listed on the Nasdaq following its merger with Ignyte Acquisition Corp in 2022.